翰宇药业：利拉鲁肽原料药获DMF First Adequate Letter

翰宇药业：利拉鲁肽原料药获DMF First Adequate Letter

翰宇药业披露利拉鲁肽原料药获得DMF First Adequate Letter的公告，公司收到了FDA下发的该DMF的《First Adequate Letter》正式信函，该信函表明翰宇药业生产的利拉鲁肽原料药通过技术审评。